Abstract 411P
Background
The cancer, which claims a million deaths per annum across India is a major concern due to presentation in later stages, owing to lack of awareness and structured screening programs. The fragmented screening happens through hospitals (HBS), rural camps by screening buses (CSB), awareness programs, and augmented self-examination (ASE) protocols using AI. This research is aimed to empower cancer screening strategies.
Methods
The effective analysis is based on the number of cancer cases detected and treated effectively. Cost data were collected as a combination of CAPEX and OPEX to do a camp and cost is derived per test using key informant interviews, patient surveys, and other publicly available data sources. A hypothetical cohort of 5,00,000 patients was assumed for assessing each strategy. One-way, two-way, and probabilistic sensitivity analyses were performed to test the robustness of the result. The methods selected were HBS, CSB &ASE.
Results
The results showed augmented self-examination is the best strategy followed by education and lastly screening vehicles. One-way analysis showed that the results were sensitive to the labor cost, but the two-way analysis showed that results are not sensitive to cancer burden. The cost of ASE for 3 cancers (oral, cervical breast) per person is INR 150, for CSB 1200 INR, and for HBS its 650 INR.
Conclusions
ASE is the way forward in developing nations followed by empowering the community health centers and the least effective is cancer screening buses.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
440P - Targeting KRAS<sup>G12C</sup>: Repurposing of potential therapeutics for the treatment of pancreatic ductal adenocarcinoma (PDAC)
Presenter: EVA RAHMAN KABIR
Session: Poster viewing 06
441P - Malignant diseases diagnosed in people living with HIV in Japan
Presenter: Kenju Ando
Session: Poster viewing 06
442P - Dose intensity and tolerance of modified FOLFIRINOX in patients with advanced cancer
Presenter: Tejaswini Adadadara
Session: Poster viewing 06
444P - Incidence of cancer diagnosis and cancer care before and after the COVID-19 pandemic in French Polynesia TEAHUPOO study
Presenter: Elodie HIRIGOYEN
Session: Poster viewing 06
445P - Development of a simple and objective prognostication model in patients with advanced solid malignant tumor treated with immune checkpoint inhibitors: A pan-cancer analysis
Presenter: Yuto Matsushita
Session: Poster viewing 06
446P - Impact of previous immunotherapy on chemotherapy efficacy in metastatic melanoma
Presenter: Meiyu Fang
Session: Poster viewing 06
447P - Clinical characteristics of 21 patients with type 1 diabetes mellitus related to immune checkpoint inhibitors
Presenter: Haruna Kameoka
Session: Poster viewing 06
448P - Prevalence of thyroid dysfunction, diabetes, and impact of palliative chemotherapy in advanced metastatic cancer patients: Prospective data from LMIC
Presenter: Amit Sehrawat
Session: Poster viewing 06
449P - The study of androgen receptor status in triple negative breast cancer patients at Medical Oncology Department, Yangon General Hospital (YGH)
Presenter: Khin Mu
Session: Poster viewing 06
450P - Are grade III well-differentiated neuroendocrine tumours a unique clinic-pathological entity?
Presenter: Jahnavi Kalvala
Session: Poster viewing 06